Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug CostsZacks Investment Research • 05/12/25
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price ReformInvestors Business Daily • 05/12/25
Amgen's TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United KingdomBusiness Wire • 05/07/25
AMGN's Key Drugs Repatha, Evenity & Blincyto Drive Q1 Sales GrowthZacks Investment Research • 05/05/25
Compared to Estimates, Amgen (AMGN) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 05/01/25
Amgen (AMGN) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresZacks Investment Research • 04/28/25